The European study enrolled 97 patients, and final data was completed for 80 patients. It showed a median volume reduction in the treated lobe of 72% in predicted responders versus 4% in predicted non-responders.
The Chartis system showed an average 27% improvement in FEV1, a standard measure of lung function, a 19% average improvement in their six-minute walk distance, and a 15-point average improvement in their reported quality of life and predicted non-responders experienced little or no benefit on average.
The Chartis assessment provides regional lung information to allow a physician to plan Epstein-Barr virus treatment in a way that maximises the potential benefit to the patient.
Felix Herth, chairman and head of pneumology and respiratory care at the University of Heidelberg in Germany, said using the Chartis system to plan Epstein-Barr virus treatment can result in benefits for emphysema patients in terms of improvement in lung function and quality of life.